Skip to main content
. 2012 Jun 20;18:1658–1667.

Table 2. Group 1 (subretinal fluid) demographics.

Patient Age Initial VA Final VA Study vitreous sample/injections
1
 85
 20/63
 20/40
 4
2
 70
 20/50
 20/20
 7
3
 66
 20/100
 20/100
 7
4*
 90
 20/50
 20/80
 7
5*
 63
 20/100
 20/63
 6
6* 73 20/63 20/32 8

* Patient 4 and 5 had intravitreal triamcinolone, at visit 8 and 6 respectively. Patient 6 was switched to ranibizumab on visits 6–7. All other injections were bevacizumab 0.05 ml/1.25 mg.